Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 27, 2010ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam)Open Access

Vascular PAR-1: Activity and Antagonism

View Full Paper
Ask AI
Bookmark
Share

Population

Patients with cardiovascular diseases, particularly acute coronary syndrome

Design

Review

Authors

NLNinian N. LangCardio-OncologyIGIngibjörg Jóna GuðmundsdóttirInterventional / Structural Cardiology
David E. Newby
David E. NewbyCardiac Imaging

Discussion

Loading...

Member takes

Implication

Hypothesis-generating for PAR-1 antagonists in atherothrombosis; leaves open validation in randomized trials.

Structured PICO

P
Population
Patients with cardiovascular diseases, particularly acute coronary syndrome
I
Intervention
PAR-1 antagonists

PAR-1 antagonists represent a potential therapeutic breakthrough by offering antiatherothrombotic benefits without the hemorrhagic side effects typical of current antiplatelet therapies.

Cite This Study

Lang et al. (2010) studied this question.

synapsesocial.com/papers/6a1bcde3b33628da419ce2a3https://doi.org/10.1111/j.1755-5922.2010.00140.x

Topics

Dual antiplatelet therapy
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Receptor Mechanism of Thrombin-Induced Endothelium-Dependent and Endothelium-Independent Coronary Vascular Effects in Dogs1993 · 65 citations
  2. 2Randomized Trial of Aspirin, Sibrafiban, or Both for Secondary Prevention After Acute Coronary Syndromes2001 · 103 citations
  3. 3Basic and Translational Research on Proteinase-Activated Receptors: Antagonism of the Proteinase-Activated Receptor 1 for Thrombin, a Novel Approach to Antiplatelet Therapy for Atherothrombotic Disease2008 · 54 citations
  4. 4Protection against thrombosis in mice lacking PAR32002 · 197 citations
  5. 5Intertwining of thrombosis and inflammation in atherosclerosis2007 · 289 citations